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Abstract
Background:  Prevention of diabetes and coronary heart disease (CHD) is possible but
identification of at-risk patients for targeting interventions is a challenge in primary care.
Methods: We analyzed electronic health record (EHR) data for 122,715 patients from 12 primary
care practices. We defined patients with risk factor clustering using metabolic syndrome (MetS)
characteristics defined by NCEP-ATPIII criteria; if missing, we used surrogate characteristics, and
validated this approach by directly measuring risk factors in a subset of 154 patients. For subjects
with at least 3 of 5 MetS criteria measured at baseline (2003-2004), we defined 3 categories: No
MetS (0 criteria); At-risk-for MetS (1-2 criteria); and MetS (≥ 3 criteria). We examined new diabetes
and CHD incidence, and resource utilization over the subsequent 3-year period (2005-2007) using
age-sex-adjusted regression models to compare outcomes by MetS category.
Results: After excluding patients with diabetes/CHD at baseline, 78,293 patients were eligible for
analysis. EHR-defined MetS had 73% sensitivity and 91% specificity for directly measured MetS.
Diabetes incidence was 1.4% in No MetS; 4.0% in At-risk-for MetS; and 11.0% in MetS (p < 0.0001 for
trend; adjusted OR MetS vs No MetS = 6.86 [6.06-7.76]); CHD incidence was 3.2%, 5.3%, and 6.4%
respectively (p < 0.0001 for trend; adjusted OR = 1.42 [1.25-1.62]). Costs and resource utilization
increased across categories (p < 0.0001 for trends). Results were similar analyzing individuals with
all five criteria not missing, or defining MetS as ≥ 2 criteria present.
Conclusion: Risk factor clustering in EHR data identifies primary care patients at increased risk
for new diabetes, CHD and higher resource utilization.
Background
Identifying individuals at risk for chronic diseases is the
first step toward preventive measures. Metabolic syn-
drome is a diagnosis that has been proposed to identify
patients in whom the clustering of risk factors is associ-
ated with increased risk of diabetes and cardiovascular
disease [1]. The risk factors included in the National Cho-
lesterol Education Program-Adult Treatment Panel III
(NCEP-ATPIII) definition are central obesity (measured
by waist circumference), dyslipidemia (high triglycerides
and low HDL), impaired glucose metabolism, and ele-
vated blood pressure. Although the underlying cause for
their clustering is not understood, these risk factors cluster
together more often than predicted by chance alone [2].
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National surveys and large population-based studies have
shown that metabolic syndrome is common [3,4] and is
associated with substantial health care costs [5]. Data
from the NHANES III estimated that 24% of the US pop-
ulation over the age of 20 fulfilled the criteria of the met-
abolic syndrome according to the NCEP-ATPIII definition
[3]. The clinical usefulness of the metabolic syndrome
diagnosis has been debated [6,7] but in fact, very few stud-
ies have reported data on metabolic syndrome in real clin-
ical practice settings. The concept of risk factor clustering
has high potential for identification of at-risk patients, but
data from real-world clinical care is needed to understand
the actual usefulness of the metabolic syndrome concept
as a marker of risk factor clustering and a target for preven-
tion of its adverse consequences.
Many hospitals and outpatient settings now have elec-
tronic-based health records (EHR) that can be queried for
clinical care research and quality improvement [8]. The
clinical information recorded in the EHR could be used
for identification of populations at risk who might benefit
from targeted preventive interventions. The opportunity
to use the EHR to identify risk factor clustering and meta-
bolic syndrome has not been investigated. From a public
health perspective, it would be efficient to use already-col-
lected clinical care information to identify individuals at
risk for developing chronic disease.
With this in mind, we hypothesized that: 1) we could
identify people with metabolic syndrome in the EHR of
our large primary care practice-based network, even when
considering the limitation of missing or misclassified
data; 2) metabolic syndrome would be associated with
higher health care utilization and costs than for people
without metabolic syndrome; and 3) people with meta-
bolic syndrome would be at increased risk for subsequent
development of diabetes or coronary heart disease (CHD)
relative to people without metabolic syndrome. Our aim
was to assess whether risk factor clustering identified in
EHR data identifies increased-risk people who might sub-
sequently benefit from prevention interventions.
Methods
Data Source and Study Patients
We identified all people receiving regular care from an
identified primary care physician in a network of 12 out-
patient practices in eastern Massachusetts affiliated with
Massachusetts General Hospital (MGH) and the Partners
Healthcare System (PHS): the MGH Primary Care Prac-
tice-Based Research Network (PBRN). PBRN practices
include three hospital-affiliated academic practices, four
community health centers, and five private practice
offices, together serving a wide range of communities and
patient populations. PBRN practices share a common
EHR containing all clinical and utilization data for each
patient. EHR data are searchable in the Research Patient
Data Repository (RPDR) http://www.lcs.mgh.har
vard.edu/projects/rpdr. html. Using the RPDR we selected
for study those patients older than 18 years (age range
from 18 to 105 years old), with at least one outpatient
visit between January 1st, 2003 and December 31st, 2004.
We queried coded field data for physical examination,
medication lists, problem lists, clinical laboratories,
demographic information including race, insurance sta-
tus, home zip code (to calculate median household
income based on Federal tax return data for that code),
and health care utilization and cost information. The
study was approved by the Massachusetts General Hospi-
tal/Partners Health Care System Institutional Review
Board.
Diagnosis of Diabetes and Coronary Heart Disease
We excluded individuals with diabetes and/or coronary
heart disease (CHD) at baseline from the primary analysis
because we wanted to assess incident diagnosis of these
conditions, and because our approach is intended to be
used for prevention of these conditions. Baseline diabetes
diagnosis was defined using a previously validated algo-
rithm that included diabetes mellitus on the problem list,
diabetes-specific medications, hemoglobin A1c (HbA1c)
results > 7.0%, or one inpatient diagnosis code or two out-
patient diagnosis codes for diabetes (ICD-9 codes 250.xx).
This algorithm has 98% sensitivity and 98% specificity for
diabetes when compared to the gold standard of manual
chart review by a trained research nurse [9]. We did not
further discriminate type 1 from type 2 diabetes. Baseline
CHD diagnosis was based on presence of coronary heart
disease defined by any one of the following three criteria:
1) one inpatient diagnosis code or two outpatient diagno-
sis codes for either coronary artery disease or myocardial
infarction (ICD-9 codes 410.x through 414.x and 429.2);
2) Current Procedural Terminology (CPT) billing codes
for coronary artery bypass grafting (CABG) or percutane-
ous insertion of an intracoronary stent; and/or 3) Evi-
dence of myocardial infarction by elevated troponin T
(greater than 0.09 ng/ml on one or more occasions). The
approach has a sensitivity of 100% and specificity of 97%
for CHD when compared to the gold standard of detailed
manual chart review [10].
Definition of Formal and Surrogate Characteristics
The thresholds for criteria used in each of the five categor-
ical characteristics of the metabolic syndrome are pre-
sented in Table 1. We used the updated NCEP-ATPIII
thresholds to define formal criteria. If formal criteria were
not available in the EHR, we queried for surrogate criteria.
Central obesity surrogate criteria cut-offs were based on
reported BMI equivalents for waist circumference in men
and women of the Framingham Offspring Study [11]. The
BMI cut-offs for men (29.1 kg/m2) and for women (27.2BMC Health Services Research 2009, 9:170 http://www.biomedcentral.com/1472-6963/9/170
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kg/m2) corresponded to the 66th percentile in the PBRN
population. If height was not available in the dataset, we
used the 66th percentile of weight in both sexes (≥ 201 lbs
in men, ≥ 162 lbs in women). The surrogate criteria for
non-fasting glucose, triglycerides and total cholesterol
were defined by thresholds used in the original, non-fast-
ing Framingham Heart Study cohort analyses [12]. If more
than one measurement for a specific criterion was availa-
ble during the baseline period, the most recent measure-
ment was used.
Classification of Metabolic Syndrome
After excluding patients meeting our EHR diagnostic crite-
ria for diabetes or CHD, we assessed the presence of meas-
ured metabolic syndrome criteria in the remaining patient
population. Once all the patients were assessed for pres-
ence or absence of measurement in the five categories of
criteria, we restricted our analysis to those patients with at
least three criteria measured. We then categorized patients
into three groups: 1) No metabolic syndrome (zero risk
factors present); 2) At-risk-for metabolic syndrome (1 or 2
risk factors present); and 3) having Metabolic syndrome
(≥ 3 risk factors present).
Validation of criteria and Metabolic Syndrome 
classification
We recruited 154 patients in one PBRN practice, the MGH
Internal Medicine Associates (IMA), to validate our
approach to classifying EHR metabolic syndrome criteria.
We invited patients to arrive 30 minutes before the time
of their regular scheduled appointment to have standard-
ized assessment of risk factors. Height and weight were
measured without shoes in light street clothing; waist cir-
cumference was measured above the iliac crest and the
average of two measurements was used. Blood pressure
was measured after the patient had been sitting for at least
5 minutes; the average of the two measurements, taken at
least 5 minutes apart, was used. Blood glucose and lipids
were drawn after an overnight fast of at least eight hours.
The thresholds for BMI and weight in the EHR used as sur-
rogate criteria (see Table 1) had a sensitivity of 88% and
specificity of 87% (c-statistic = 0.876) to predict central
obesity defined by waist circumference >40" in men, and
>35" in women. The other criteria had c-statistics between
0.678 and 0.855 (see Additional file 1: Table S1 for details
on each criterion). Meeting at least 3 criteria in the EHR
had a sensitivity of 73% and a specificity of 91% for
detecting metabolic syndrome measured in a standard-
ized fashion (c-statistic = 0.818). These validation data
confirmed that we could use the EHR to identify reliably
individuals with metabolic syndrome in primary care
practices.
Outcomes assessment
We queried the RPDR database over the time period from
January 1st 2005 up to December 31st, 2007. The RPDR
includes patient utilization, cost, problem and discharge
diagnosis lists, and hospital-based medication data. We
used the RPDR to query billing data (principal and sec-
ondary diagnoses and procedures, inpatient and outpa-
tient total, direct, and itemized costs, hospital charges
including provider, type of service and date) and other
administrative information (primary care physician, hos-
pital admissions and emergency room visits, hospital
length of stay, admission service, and discharge disposi-
Table 1: Formal and surrogate metabolic syndrome characteristics used to define electronic health record metabolic syndrome 
categories.
Metabolic syndrome criteria Formal NCEP-ATPIII characteristic Surrogate characteristic
Central obesity Waist circumference >102 cm (40") in men, >88 cm 
(35") in women
Body mass index ≥ 29.1 kg/m2 in men, ≥ 27.2 kg/m2 in 
women;
if height missing, weight ≥ 94.4 kg (201 lbs) in men, ≥ 
73.6 kg (162 lbs) in women*
Elevated blood pressure ‡ Average of last two readings ≥ 130 and/or ≥ 85 mmHg 
or diagnosis of hypertension on problem list and 
antihypertensive agent on medication list
Any of: one blood pressure ≥ 130 and/or ≥ 85 mmHg; 
on anti-hypertensive medication but no diagnosis on 
problem list; hypertension from billing codes
Elevated glucose Fasting plasma glucose >5.6 mmol/L (100 mg/dL) Any plasma glucose ≥ 7.8 mmol/L (140 mg/dL)
Elevated triglycerides Fasting plasma level ≥ 1.7 mmol/L (150 mg/dL) Any plasma level ≥ 2.3 mmol/L (200 mg/dL)
Low HDL cholesterol Plasma level <1.0 mmol/L (40 mg/dL) in men, <1.3 
mmol/L (50 mg/dL) in women
Plasma total cholesterol >5.2 mmol/L (200 mg/dL)
*BMI cut-offs chosen based on report of waist circumference equivalent from the Framingham Offspring Study; weight cut-offs corresponding to the 
66th percentile of available weights in the population (percentile based on the percentile of the values for the cut-offs for BMI)
‡ All patients in our dataset had available data to assess formal criteria of blood pressure, so the surrogate criteria were not used in the present 
analysisBMC Health Services Research 2009, 9:170 http://www.biomedcentral.com/1472-6963/9/170
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tion). The health resources-related outcomes of interest
included the number of hospital inpatient admissions,
total cost per admission, length of stay, and number of
outpatient visits. New diagnoses of diabetes and CHD
over the 3-year follow-up were identified using the same
validated algorithms described above.
Statistical analysis
We restricted our analysis to those patients with at least
three measured metabolic syndrome traits, in the frame-
work of case finding in a broad population of usual care
patients where some missing data are expected. Primary
analyses were conducted using metabolic syndrome
defined as having three or more risk factors present. Out-
comes were log-transformed to improve normality when
appropriate. Health resource outcomes were analyzed
using age-sex adjusted linear regression models; p-values
are reported for trend across metabolic syndrome catego-
ries (No metabolic syndrome, At-risk-for metabolic syndrome,
and  Metabolic syndrome) or across four categories (the
three metabolic syndrome categories plus patients with
diabetes and/or CHD at baseline). Diabetes and CHD
incidence were analyzed using age-sex-adjusted logistic
regression models; p-values are reported for trends across
the three metabolic syndrome categories. Odds ratios
(age-sex-adjusted) were calculated to compare patients in
the Metabolic syndrome or the At-risk-for metabolic syndrome
groups to individuals in the No Metabolic syndrome group.
Population attributable risk proportion (PAR) was calcu-
lated using the formula: pd ([RR-1]/RR) where pd = pro-
portion of cases exposed to the risk factor, and RR =
relative risk [13].
We conducted subsidiary analyses using only the patients
having all five criteria measured to assess prevalence of
metabolic syndrome and to compare our population to
national data. Another set of subsidiary analyses was con-
ducted to assess outcomes using a more sensitive (but less
specific) approach, to consider the perspective of identify-
ing a wider population that might benefit from larger
scale prevention approaches. For this, we used the popu-
lation with at least 3 criteria measured but defined the
presence of metabolic syndrome as meeting two or more
criteria. With this approach, EHR metabolic syndrome (≥
2 criteria) had a sensitivity of 91% and a specificity of 76%
for directly-phenotyped metabolic syndrome (≥ 3 crite-
ria). Finally, we conducted a sensitivity analysis using all
patients in the dataset (including individuals with less
than 3 criteria measured).
We used SAS for all analyses (SAS v 9.1, SAS Institute Inc.,
Cary, North Carolina), and considered p-values < 0.05 to
indicate statistical significance. The authors had full access
to the data and take responsibility for its integrity.
Results
There were 122,715 patients available for analysis in the
baseline period, including 17,320 patients with diabetes
and/or CHD. The remaining 105,395 patients were evalu-
ated for the presence of measured formal or surrogate
metabolic syndrome criteria as defined in Table 1. In this
population, 0% had a waist circumference recorded; trig-
lycerides and glucose were measured in the fasting state in
only 21.0% and 17.2%, respectively. Distributions of the
formal and surrogate criteria among all patients without
diabetes or CHD and among those with at least three cri-
teria measured are shown in Additional file 1: Table S2. Of
the 105,395 patients without diabetes or CHD, 78,293
patients had at least 3 metabolic syndrome criteria meas-
ured and are the subject of this analysis. Demographic
characteristics are presented in Table 2. Individuals in the
Metabolic syndrome category were older, more likely to be
male, more likely to be insured by Medicare, and to have
a lower mean annual income compared to patients in the
No metabolic syndrome or At-risk for metabolic syndrome cat-
egories.
Health care utilization from 2005 to 2007 is presented in
Table 2 by metabolic syndrome category and presence of
diabetes and/or CHD. Patients with diabetes/CHD used
more health care resources and were more costly overall
(all p-values < 0.0001). Across categories of metabolic
syndrome, trends for increased number of admissions,
cost per admission, length of stay, and number of outpa-
tients visit all were significant (all p-values < 0.0001), with
the patients having Metabolic syndrome using more health
care resources than those without.
Diabetes incidence was increased across metabolic syn-
drome categories (p < 0.0001 for trend), with the patients
in the Metabolic syndrome group being at the highest risk
(11.0%) of new diabetes over 3 years. Compared to the No
metabolic syndrome group, the age-sex-adjusted OR for new
cases of diabetes in patients was 2.39 (2.26-2.64) for peo-
ple At-risk-for and 6.86 (6.06-7.76) for individuals with
Metabolic syndrome (P < 0.0001); the PAR for diabetes was
38.1% and 25.3% in each of those two categories. CHD
incidence was also increased among people At-risk-for or
with Metabolic syndrome, with those with Metabolic syn-
drome having the highest incidence of new CVD (6.4%
over 3-year follow-up; p < 0.0001 for trend). Compared to
the No metabolic syndrome group, the age-sex-adjusted OR
for new cases of CHD was 1.20 (1.11-1.30) for people At-
risk-for and 1.42 (1.25-1.62) for individuals with Metabolic
syndrome (P < 0.0001); the PAR for CHD was 7.6% and
2.5% in each of those two categories.
Subsidiary analyses
To assess whether missing data for metabolic syndrome
criteria distorted the analysis in any way, we conductedBMC Health Services Research 2009, 9:170 http://www.biomedcentral.com/1472-6963/9/170
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subsidiary analyses among 30,461 patients who had all
five criteria measured (that is, no missing data) in the
EHR. Additional file 1: Table S2 shows the prevalence of
patients meeting formal and surrogate criteria (after exclu-
sion of diabetes and CHD) in the population with all five
criteria measured. It is clear that missing data resulted in
lower prevalences of metabolic syndrome characteristics
in the classification that used patients with only three or
more criteria measured. To assess effects of missing data,
we repeated the main analysis using subjects with no
missing data. We found that baseline characteristics and
outcomes were very similar to those when found when
analyzing the population of patients with at least three cri-
teria measured (see Table 3). In this sub-group with all
five criteria measured, compared to the No metabolic syn-
drome group, the age-sex-adjusted OR for new cases of dia-
betes in patients was 2.77 (2.25-3.42) for people At-risk-
for and 8.67 (6.98-10.77) for individuals with Metabolic
syndrome (P < 0.0001). Compared to the No metabolic syn-
drome  group, the age-sex-adjusted OR for new cases of
CHD was 1.44 (1.22-1.69) for people At-risk-for and 1.91
(1.58-2.32) for individuals with Metabolic syndrome (P <
0.0001). Thus, while missing data affected the prevalence
of metabolic syndrome characteristics it had a negligible
effect on the association of EHR metabolic syndrome on
adverse outcomes.
Using our primary approach only 6.6% (5,185 out of
78,293) of the population with at least three risk factors
measured was classified as having metabolic syndrome
Table 2: Baseline characteristics and three-year health care utilization (2005-2007) for individuals with No metabolic syndrome, At-risk-
for metabolic syndrome, with Metabolic syndrome, and with diabetes and/or coronary heart diseases (CHD) according to electronic 
health record data
No metabolic 
syndrome*
At-risk-for metabolic 
syndrome*
Metabolic syndrome* Any diabetes/
CHD
0 criteria 1-2 criteria ≥ 3 criteria
Baseline characteristics
N 36,841 36,267 5,185 17,320
Age, years (SD) 45 (15) 49 (16) 52 (14) 64 (16)
Women, % 62.8% 57.4% 48.6% 48.0%
Race (% White) 78.8% 76.5% 78.5% 79.3%
Insurance
Insurance
% Commercial
77.4% 66.1% 62.2% 35.1%
% Medicare 10.6% 18.3% 20.4% 5.4%
Income, $US (SD) $81,402
($59,796)
$70,551
($53,479)
$62,101
($45,643)
$64,190 (49,551)
Three-year outcomes p-value† p-value‡
Inpatient admissions, 
mean number per 
patient (SD)
0.12 (0.61) 0.23 (1.07) 0.35 (1.20) 1.5 (3.6) <.0001 <.0001
Length of stay, mean 
days (SD) §
4 (3) 5 (3) 6 (3) 12 (3) <.0001 <.0001
Outpatient clinic visits, 
mean number per 
patient (SD) §
4.3 (2.3) 6.6 (2.5) 10.4 (2.5) 20.5 (2.5) <.0001 <.0001
Total cost, US dollars 
(SD) §
$3,054 ($4) $4,136 ($4) $5,057 ($4) $9,177 ($4) <.0001 <.0001
Incidence of diabetes 
mellitus
1.4% 4.0% 11.0% N/A <.0001 N/A
Incidence of CHD 3.1% 5.3% 6.4% N/A <.0001 N/A
* Individuals categorized after exclusion of diabetes and CHD, including only patients with at least three criteria (formal or surrogate) measured (n 
= 78,293) using electronic health record data from 2003-2004
† p-values for trend in age-sex-adjusted regression analysis in all 3 categories of metabolic syndrome status (No metabolic syndrome, At-Risk-for 
metabolic syndrome, and with Metabolic syndrome)
‡ p-values for trend in age-sex-adjusted regression analysis in all 4 categories (No metabolic syndrome, At-Risk-for metabolic syndrome, with Metabolic 
syndrome, and any diabetes and/or CHD)
§log-transformed for analysis and then back-transformed for displayBMC Health Services Research 2009, 9:170 http://www.biomedcentral.com/1472-6963/9/170
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defined as meeting three or more criteria. This low preva-
lence is due to exclusion of diabetes and CHD before clas-
sifying patients with metabolic syndrome, and to missing
data. To compare this EHR metabolic syndrome preva-
lence to national data [3], we performed analyses includ-
ing patients with diabetes and CHD and with no missing
data. Overall, 39,733 patients had all five criteria meas-
ured in the 2003-2004 EHR and 9,170 of these (23%)
were classified as having Metabolic Syndrome, a rate very
similar to that reported in the literature for white U.S.
adults.
We conducted another set of subsidiary analyses to assess
the approach using a more sensitive but less specific cut-
off to identify patients with metabolic syndrome (EHR
metabolic syndrome diagnosed with two or more criteria
present; see Additional file 1: Table S3). Even with this less
specific definition of metabolic syndrome, all outcomes
were less favorable across metabolic syndrome categories
(p-value < 0.0001 for all trends). Using this approach, the
PAR of EHR metabolic syndrome was 38.6% for diabetes
and 8.0% for CHD risk.
Finally, the sensitivity analysis using all patients in the
dataset (shown in Additional file 1: Table S4) confirmed
our results in the main analysis: the patients meeting only
1-2 criteria were at increased risk compared to the No met-
abolic syndrome group, even in this larger dataset with
more missing values.
Discussion
Identification of individuals at risk for diabetes and CHD
is the first step for primary prevention. Metabolic syn-
drome has received great fanfare for its putative value to
identify at-risk patients for prevention interventions,
despite a paucity of data about its actual performance in
usual clinical care settings. We have demonstrated here
that it is possible to identify patients at risk of developing
diabetes and CHD by identifying risk factor clustering
using a looser-than-formal metabolic syndrome defini-
tion based on combining formal and surrogate criteria
available in the EHR of a large primary care network. A
looser set of definitions was needed to account for the
missing information that is characteristic of usual care
data, especially obesity measures and indication of fasting
status. Despite missing data, the validation study demon-
strated that our approach to define EHR metabolic syn-
drome was 91% specific to identify patients with
formally-diagnosed metabolic syndrome. Even a less spe-
cific, more sensitive approach to the definition identified
patients at risk for adverse consequences of risk factor
clustering.
Table 3: Characteristics and outcomes of individuals classified as No metabolic syndrome, At-risk-for metabolic syndrome, and with 
Metabolic syndrome using individuals with all five criteria measured*
No metabolic syndrome* At-risk-for metabolic 
syndrome*
Metabolic syndrome*
0 criteria 1-2 criteria 3 or more
Baseline characteristics
N = 30,461 9,529 16,674 4,258
Age, years (SD) 45 (14) 51 (15) 52 (14)
Women, % 65.8% 59.9% 51.2%
Race (% White) 76.9% 76.0% 78.1%
Insurance (% Commercial) 80.2% 66.4% 61.2%
Income, $US (SD) $80,859 ($60,623) $69,846 ($54,333) $61,086 ($45,290)
Three-year outcomes p-value †
Inpatient admissions, mean number 
per patient (SD)
0.10 (0.52) 0.23 (1.07) 0.36 (1.25) <.0001
Length of stay, mean days (SD) § 4 (3) 6 (3) 6 (3) <.0001
Outpatient clinic visits, mean number 
per patient (SD) §
4.3 (2.2) 7.2 (2.5) 11.0 (2.4) <.0001
Total cost, US dollars
(SD) §
$3,804 ($4) $4,665 ($4) $5,271 ($4) <.0001
Incidence of diabetes mellitus 1.1% 3.7% 11.0% <.0001
Incidence of CHD 2.1% 4.7% 6.5% <.0001
*patients categorized after excluding patients with diabetes and/or CHD, having all five criteria measured (formal or surrogate); prevalence of each 
risk factor were 40.8% for obesity, 35.6% for blood pressure, 25.1% for HDL, 18.6% for triglycerides, and 6.7% for glycemia.
† p-values for trend in age-sex-adjusted regression analysis in all three categories of metabolic syndrome status
§log-transformed for analysis and then back-transformed for displayBMC Health Services Research 2009, 9:170 http://www.biomedcentral.com/1472-6963/9/170
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Using a simple diagnostic algorithm, the patients identi-
fied in the EHR as having Metabolic syndrome were more
than 6 times more likely to develop diabetes, about 42%
more likely to develop CHD, and to have higher health
resource utilization and health care costs over three years
of follow-up compared with individuals identified as not
meeting metabolic syndrome diagnosis. The higher health
care utilization costs in patients with metabolic syndrome
are in accordance with other studies. Curtis et al. found
that individuals with the metabolic syndrome increased
Medicare health care total costs by 20% to 30% [14]. In
individuals with all 5 criteria measured, ORs for increased
risk of diabetes (OR = 8.67) and CHD (OR = 1.91) are also
concordant with published literature: in studies with com-
plete, standardized phenotyping individuals with the
metabolic syndrome are about 3-6 times more likely to
develop diabetes and to have twice the risk for CHD
[1,15,16]. As shown in other reports, our results argue in
favor of metabolic syndrome being a stronger predictor of
incident diabetes than CHD [16,17]. In addition, we
found that patients diagnosed with diabetes or CHD at
baseline had about twice the utilization rates and costs
compared with patients with EHR metabolic syndrome.
These data support the notion that risk factor clustering is
identifiable in usual clinical care, is associated with more
adverse health outcomes over time, but is less costly than
its full-blown diabetes and CHD outcomes. The data
argue for the value of risk factor clustering as embodied in
metabolic syndrome as a high-risk state amenable to and
worthy of detection to prevent transitions from the lower-
cost 'risk state' to the higher-cost 'outcome state' of
chronic disease management.
Missing data could potentially have biased our findings.
Using the data from patients having all five criteria meas-
ured and including patients with diabetes and CHD, the
prevalence of EHR metabolic syndrome (23%) in our
population was very similar to national data: in the
NHANES, 20% to 25% of the US population had meta-
bolic syndrome [3]. Once we removed diabetes and CHD,
the results from this subsidiary analysis (with all five cri-
teria measured) was very similar to the results using our
primary approach (with ≥ three criteria measured). Our
approach allowing up to two missing characteristics
makes greater use of the available clinical care data with
no apparent cost to the validity of the approach. Indeed,
our primary algorithm allowed us to classify three-quar-
ters of all patients in the population into one of three met-
abolic syndrome categories despite the relatively high
prevalence of missing data. Since most of the metabolic
syndrome criteria (when adapted to include surrogate
measures) are typically measured in primary care practice,
this means that usual care electronic databases have the
potential to be useful clinic population-wide to identify
groups of patients at risk for diabetes and CHD. Analysis
using individuals with all five criteria measured allowed
us to compare our results to other reports and national
data of prevalence of metabolic syndrome, but the algo-
rithm using all patients with at least three criteria meas-
ured allows identification of a higher number of
individuals with metabolic syndrome with high specifi-
city.
Individuals with metabolic syndrome benefit from per-
sonalized lifestyle interventions to decrease metabolic
abnormalities and prevent diabetes [18]. One of the issues
of primary prevention is how to identify patients with
"prediabetes" since they are rarely aware of their condi-
tion and physicians seldom formally diagnose patients
with metabolic syndrome [19]. Our primary, more spe-
cific approach (≥ three criteria) allows case-finding for
high risk patients for intensive lifestyle interventions to
prevent diabetes. Alternatively, the more sensitive but less
specific approach (≥ two criteria) identified a larger group
of patients and could be useful for larger scale interven-
tions such as targeted screening with information letters
or invitations to group education sessions. Our cost data
highlight the potential value to health care systems of
metabolic syndrome detection for diabetes and CHD pre-
vention.
Strengths and limitations
Strengths of this study include analysis of a very large
number of patients, data from a primary care practice net-
work representing real-world clinical care, and prospec-
tive follow-up of outcomes. We included all individuals
using health care in the network, with no upper age limit,
but only 1% of the patients were 85 years old or above at
baseline, so this age range should not affect the main
results. We identified diabetes and CHD in the EHR using
a validated algorithm, so we are confident that the out-
comes represent true incident cases. One limitation was
the use of surrogate criteria when the formal criteria were
not measured: our validation study showed that EHR met-
abolic syndrome (using both formal and surrogate crite-
ria) had outstanding specificity (91%) for directly-
assessed metabolic syndrome. Missing data were a con-
cern and many of the patients in the At-risk-for metabolic
syndrome group would probably fall into the category Met-
abolic syndrome if all five criteria would have been availa-
ble for all patients. This limitation was addressed by an
analysis of patients with all five criteria measured that
confirmed our primary findings. Also, missing data and
misclassification would likely reduce our ability to detect
differences between groups, so our primary results proba-
bly underestimate actual effects.
Conclusion
In summary, metabolic syndrome has been extensively
studied in highly standardized population samples andBMC Health Services Research 2009, 9:170 http://www.biomedcentral.com/1472-6963/9/170
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national surveys, but very little is known about its preva-
lence and consequences in real-world primary care prac-
tice. Our data shed light on outcomes of free-living
patients with metabolic syndrome in usual primary care.
EHR data and metabolic syndrome diagnosis both have
their limitations, but together they could be a powerful
tool to identify patients and populations at risk. Using a
simple risk factor clustering algorithm based on metabolic
syndrome criteria, EHR can be used to identify individuals
at high risk of developing diabetes and CHD and
increased health care utilization. We believe that identifi-
cation of at-risk individuals in this manner should be use-
ful to improve care, target lifestyle interventions for
primary prevention of diabetes and CHD, and reduce
health care cost and resources utilization associated with
risk factor clustering.
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